.

BioPharmaceutical Business Intelligence

  • Analyze global market entry opportunities
  • Uncover prior art in expired and abandoned patents
  • Obtain formulation and manufacturing information

Upgrade to enjoy subscriber-only features like email alerts and data export. See the Plans and Pricing

Serving leading biopharmaceutical companies globally:

Teva
Mallinckrodt
Covington
Colorcon
Cerilliant
Cipla
Moodys
Farmers Insurance
Julphar
Accenture

Generated: December 16, 2017

DrugPatentWatch Database Preview

Claims for Patent: 5,886,035

« Back to Dashboard

Claims for Patent: 5,886,035

Title: Difluoroprostaglandin derivatives and their use
Abstract:A fluorine-containing prostaglandin derivative of the formula (1) (or a salt thereof) and a medicine containing it, particularly, a preventive or therapeutic medicine for an eye disease: ##STR1## wherein A is a vinylene group or the like, R.sup.1 is an aryloxyalkyl group or the like, R.sup.2 and R.sup.3 are hydrogen atoms or the like, and Z is OR.sup.4 (wherein OR.sup.4 is a hydrogen atom or an alkyl group) or the like.
Inventor(s): Shirasawa; Eiichi (Ikoma, JP), Kageyama; Masaaki (Ikoma, JP), Nakajima; Tadashi (Ikoma, JP), Nakano; Takashi (Yokohama, JP), Mori; Nobuaki (Yokohama, JP), Sasakura; Hideshi (Yokohama, JP), Matsumura; Yasushi (Yokohama, JP), Morizawa; Yoshitomi (Yokohama, JP)
Assignee: Asahi Glass Company Ltd. (Tokyo, JP) Santen Pharmaceutical Co., Ltd. (Osaka, JP)
Application Number:08/993,017
Patent Claims: 1. A fluorine-containing prostaglandin derivative of the following formula (1) or a salt thereof: ##STR4## wherein A is an ethylene group, a vinylene group, an ethynylene group, --OCH.sub.2 -- or --SCH.sub.2 --,

R.sup.1 is a substituted or unsubstituted aryloxyalkyl group,

each of R.sup.2 and R.sup.3 which are independent of each other, is a hydrogen atom or an acyl group, or forms a single bond together with Z,

X is --CH.sub.2 --, --O-- or --S--,

Z is --OR.sup.4, --NHCOR.sup.5, --NHSO.sub.2 R.sup.6 or --SR.sup.7, or forms a single bond together with R.sup.2 or R.sup.3,

each of R.sup.4, R.sup.5, R.sup.6 and R.sup.7 which are independent of one another, is a hydrogen atom, an alkyl group, an alkenyl group, an alkynyl group, a cycloalkyl group, an aryl group or an aralkyl group,

and a dual line consisting of solid and broken lines is a single bond, a cis-double bond or a trans-double bond.

2. The compound according to claim 1, wherein R.sup.1 is a phenoxymethyl group, a 3,5-dichlorophenoxymethyl group or a 3-chlorophenoxymethyl group.

3. The compound according to claim 1, which is 16-phenoxy-15-deoxy-15,15-difluoro-17,18,19,20-tetranorprostaglandin F.sub.2.alpha., 16-(3-chlorophenoxy)-15-deoxy-15,15-difluoro-17,18,19,20-tetranorprostagla ndin F.sub.2.alpha., 16-phenoxy-15-deoxy-15,15-difluoro-13,14-dihydro-17,18,19,20-tetranorprost aglandin F.sub.2.alpha. or an alkyl ester or a salt thereof.

4. A medicine containing the compound according to claim 1 as an active ingredient.

5. The medicine according to claim 4, which is a preventive or therapeutic medicine for an eye disease.

6. The medicine according to claim 5, wherein the eye disease is glaucoma or ocular hypertension.

7. The medicine according to claim 4, 5 or 6, wherein A is an ethylene group or a vinylene group.

8. The medicine according to claim 4, 5 or 6, wherein X is --CH.sub.2 --.

9. The medicine according to claim 4, 5 or 6, wherein both R.sup.2 and R.sup.3 are hydrogen atoms.

10. The medicine according to claim 4, 5 or 6, wherein Z is --OR.sup.4.

11. The medicine according to claim 9, wherein R.sup.1 is a phenoxymethyl group, a 3,5-dichlorophenoxymethyl group or a 3-chlorophenoxymethyl group.

12. A medicine containing 16-phenoxy-15-deoxy-15,15-difluoro-17,18,19,20-tetranorprostaglandin F.sub.2.alpha., 16-(3-chlorophenoxy)-15-deoxy-15,15-difluoro-17,18,19,20-tetranorprostagla ndin F.sub.2.alpha., 16-phenoxy-15-deoxy-15,15-difluoro-13,14-dihydro-17,18,19,20-tetranorprost aglandin F.sub.2.alpha. or an alkyl ester or salt thereof as an active ingredient.

13. The medicine according to claim 12, which is a preventive or therapeutic medicine for an eye disease.

14. The medicine according to claim 13, wherein the eye disease is glaucoma or ocular hypertension.
« Back to Dashboard

For more information try a trial or see the plans and pricing

Serving leading biopharmaceutical companies globally:

Novartis
Express Scripts
Federal Trade Commission
Baxter
Citi
Boehringer Ingelheim
Cantor Fitzgerald
QuintilesIMS
Julphar
Argus Health

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.

Copyright 2002-2017 thinkBiotech LLC
ISSN: 2162-2639

Secure SSL Encrypted
Privacy and Cookies
Terms & Conditions

Follow DrugPatentWatch:

botpot